FBXO7

FBXO7

• UniProt: Q9Y3I1 (FBXO7/PARK15) · batch: proteostasis-batch-2026-06-13 (Falcon DR) · review status: COMPLETE
• PN placement: 3 rows, ALP+UPS. (1) ALP|Autophagy substrate selection|…|Mitophagy|PINK/PRKN pathway; (2) UPS|Ubiquitin and UBL proteins|UBL domain|E3 ligases|CUL1 receptor / F-box; (3) UPS|E3 ubiquitin and UBL ligases|Cul1 substrate receptor|F-box|PI31, UBL. PN-node mapping: mitophagy type=mapped/ok→GO:0000423 (more_specific_than_existing_goa); UBL-domain CUL1-receptor subtype + Cul1-receptor group both=mapped/ok→GO:1990756 (already_in_goa_exact); UBL-domain class/group/type held context_only (too_broad)→GO:0061630/0043130/0019787.
• Consistency: Fully consistent across the SPECIAL CASE roles. Falcon DR, review YAML, and all three PN rows converge: FBXO7 is (a) an SCF substrate receptor (GO:1990756, ACCEPT, already in GOA), (b) a PINK1/PRKN-pathway mitophagy regulator (PARK15), and (c) a PSMF1/PI31 proteasome regulator via the FP domain; plus CDK6/cyclin-D activation. No contradictions.
• PN story / NEW pressure: No new term pressure. GO:1990756 already in GOA (PN flags already_in_goa_exact) and accepted. The mitophagy role: PN projects GO:0000423 mitophagy (verified real) but self-flags more_specific_than_existing_goa; the review more accurately uses the regulator terms GO:1903599 (positive regulation of autophagy of mitochondrion) and GO:1901526 (positive regulation of mitophagy), both verified real, ACCEPT — FBXO7 facilitates/regulates mitophagy rather than being core autophagy machinery. Review also adds SCF-independent GO:0030674 protein-macromolecule adaptor activity for the mitophagy and PI31 roles. Conclude: all roles already captured; PN mitophagy term is appropriately broader and acknowledged as such.
• Mapping strategy: Gene supports the multi-branch node design. KEY PATTERN holds for the UPS rows (F-box receptor → GO:1990756; catalytic GO:0061630 held too_broad at class). For the ALP row, the PN process term GO:0000423 is broader than the review's regulator terms — consistent with the TOMM20/HSPA8/RAB7A precedent that the broader process term should not over-claim; PN's more_specific_than_existing_goa flag captures this correctly. Scopes sound.
• Evidence alignment: PN cites the FBXO7/Parkin mitophagy paper (Burchell et al., Nat Neurosci — PMID:23933751) for row 1 and "15340381 / rev" for row 3. Review uses PMID:23933751 (mitophagy IBA/IDA support), the FP-domain/PI31 structural work (PMID:16782869-class, GO:0046982), CDK6 interaction studies, plus Falcon DR. Good overlap on the mitophagy primary reference; review enriches with proteasome/CDK6 literature.
• Verdict: Consistent across all three PN rows; GO:1990756 already in GOA, mitophagy handled via more specific regulator terms (GO:1903599/GO:1901526). No over-reach; PI31/CDK6/NF-kB roles appropriately placed.
• Recommended edits: none to FBXO7-ai-review.yaml; PN mappings sound (mitophagy more_specific_than_existing_goa flag is the correct treatment).